GlassScriptPhysician profile
Steven Vincent Priest
NPI 1083645287
$7,269.99
in general payments reported to CMS, 2019-2025
21 companies · $757 in 2025
The $757 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $951 · 2021: $955 · 2022: $906 · 2023: $1,841 · 2024: $818 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935 · Travel and Lodging: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,935.24 |
| Travel and Lodging | $480.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,183.61 | 2019-2025 | Aveir, Gallant, Jot Dx |
| Medtronic, INC. | $1,741.63 | 2021-2025 | Micra, Corevalve Evolut R, Aurora Ev-Icd Mri Surescan |
| Cvrx, INC. | $1,010.00 | 2020-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $516.40 | 2019-2023 | Xarelto |
| Abiomed | $415.21 | 2022-2024 | Impella |
| Medtronic Vascular, INC. | $298.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $178.67 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $178.25 | 2019-2022 | |
| Amgen INC. | $159.53 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $136.88 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $97.73 | 2021 | |
| Philips North America LLC | $67.78 | 2023 | |
| Pfizer INC. | $61.35 | 2019-2024 | |
| Acist Medical Systems, INC. | $59.10 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.00 | 2019-2024 | Lifevest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.08 | 2022-2023 | Jardiance |
| Astellas Pharma US INC | $30.36 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.99 | 2019 | |
| Irhythm Technologies, INC. | $23.14 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.04 | 2020 | |
| Cardiovascular Systems INC. | $6.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Priest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.